ALTME.PA
Price:
$0.0745
Market Cap:
$7.20M
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck Sharp & Dohme Corp. to study NOX-A12 combined with Keytruda and two ...[Read more]
Industry
Biotechnology
IPO Date
2016-09-30
Stock Exchange
EURONEXT
Ticker
ALTME.PA
According to TME Pharma N.V.’s latest financial reports and current stock price. The company's current Enterprise Value is 4.50M. This represents a change of 156.90% compared to the average of 1.75M of the last 4 quarters.
The mean historical Enterprise Value of TME Pharma N.V. over the last ten years is 17.84M. The current 4.50M Enterprise Value has changed 2.42% with respect to the historical average. Over the past ten years (40 quarters), ALTME.PA's Enterprise Value was at its highest in in the December 2015 quarter at 43.49M. The Enterprise Value was at its lowest in in the June 2022 quarter at -805058.55.
Average
17.84M
Median
9.92M
Minimum
75.28K
Maximum
47.91M
Discovering the peaks and valleys of TME Pharma N.V. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 66.75%
Maximum Annual Enterprise Value = 47.91M
Minimum Annual Increase = -92.73%
Minimum Annual Enterprise Value = 75.28K
Year | Enterprise Value | Change |
---|---|---|
2023 | 75.28K | -92.73% |
2022 | 1.04M | -89.67% |
2021 | 10.02M | 1.94% |
2020 | 9.83M | 66.75% |
2019 | 5.89M | 29.36% |
2018 | 4.56M | -70.14% |
2017 | 15.25M | -57.58% |
2016 | 35.96M | -24.93% |
2015 | 47.90M | -0.01% |
The current Enterprise Value of TME Pharma N.V. (ALTME.PA) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
3.71M
5-year avg
5.37M
10-year avg
17.84M
TME Pharma N.V.’s Enterprise Value is
Company | Enterprise Value | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TME Pharma N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like TME Pharma N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is TME Pharma N.V.'s Enterprise Value?
What is the highest Enterprise Value for TME Pharma N.V. (ALTME.PA)?
What is the 3-year average Enterprise Value for TME Pharma N.V. (ALTME.PA)?
What is the 5-year average Enterprise Value for TME Pharma N.V. (ALTME.PA)?
How does the current Enterprise Value for TME Pharma N.V. (ALTME.PA) compare to its historical average?